Oncolytics Biotech Engages at RBC Healthcare Conference
Oncolytics Biotech to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...
Oncolytics Biotech Shares Q1 Update and Outlook
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In ...
Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that ...
Express News | Oncolytics Reports Acceptance Of Two Abstracts At The 2024 American Society Of Clinical Oncology Annual Meeting
Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech Sets Virtual Annual Meeting
Oncolytics Biotech Eyes Milestone in Breast Cancer Trial
Oncolytics Biotech Targets FDA Approval for Cancer Drug
Oncolytics Seeking FDA Meeting to Discuss Registration-enabling Study
Express News | Oncolytics Biotech Has Submitted Type C Meeting Request To FDA For Q2 2024 To Discuss The Company's Planned Registration-enabling Trial For Pelareorep In HR+/HER2- Metastatic Breast Cancer
Oncolytics Biotech Reports Submission Of A Type C Meeting Request To FDA
This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). "We hope to meet with the agency in Q2 2024 and look forward
Oncolytics Biotech Inc Price Target Announced at C$3.00/Share by Raymond James
Oncolytics Biotech Inc Price Target Announced at C$3.00/Share by Raymond James
Oncolytics Biotech Showcases at Oncology Conference
Oncolytics Biotech to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
Biotech's Role in Addressing the Pancreatic Cancer Emergency
USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today....
Earnings Call: Oncolytics Biotech Reports Progress and Plans for Pelareorep
Oncolytics Biotech (NASDAQ:ONCY) discussed its operational highlights and financial results for the Fourth Quarter and Full Year 2023 in a recent earnings call.
No Data